Active Recombinant Mouse Pcsk9 protein(Met1-Gln694), His-tagged

• Cat.No.: Pcsk9-803M
• Product Overview: Recombinant Mouse Pcsk9 protein(NP_705793.1)(Met1-Gln694), fused with C-terminal His tag, was expressed in HEK293.

Specification

• similar: Pcsk9
• Alias: PCSK9; proprotein convertase subtilisin/kexin type 9; NARC-1; convertase subtilisin; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409
• Source: HEK293
• Species: Mouse
• Conjugate: C-His
• Tag: His
• Protein length: Met1-Gln694
• Form: Lyophilized from sterile 15mM Tris, 90mM NaCl, 50% Glycerol, pH 7.5. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• MolecularMass: The secreted recombinant mouse PCSK9 consists of 671 amino acids and has a calculated molecular mass of 72.6 kDa. As a result of proteolysis and glycosylation, the recombinant protein migrates as doublet with apparent molecular mass of approximately 19 & 65 kDa, cprresponding to the prodomain and the mature form of PCSK9 respectively in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
• GeneName: Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Mus musculus ]
• GeneNameWeblink: 100102
• OfficialSymbol: Pcsk9
• OfficialSymbolWeblink: 100102
• GeneID: 100102
• GeneIDWeblink: 100102
• mRNARefseq: NM_153565
• mRNARefseqWeblink: NM_153565.2
• ProteinRefseqWeblink: NP_705793.1
• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; NARC-1; convertase subtilisin; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409

Gene Information

• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; NARC-1; convertase subtilisin; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.